Surrozen submits FDA IND for SZN-8141 in diabetic macular edema
SRZN•DUET trial timeline
The company said the DUET Phase 1b/2a trial is expected to start by year-end 2026, with initial data targeted for H2 2027.
FDA IND submitted for SZN-8141
Surrozen submitted an IND application to the FDA to begin clinical testing of SZN-8141 for diabetic macular edema.
